For Immediate Release:
Contact: Kelly Broadway, 202-808-8853
[email protected]
Washington, D.C. – The Council for Affordable Health Coverage (CAHC) applauds Senators Mullin (R-OK), Sinema (I-AZ), Tim Scott (R-SC), and Hassan (D-NH) for introducing the Medicaid VBPs for Patients (MVP) Act.
The Act, which has support from payers, patients, and drug companies, supplements a Centers for Medicare & Medicaid Services rule allowing public and private payers to voluntarily enter value-based (VBA) arrangements with drug manufacturers. Reimbursement is then based on the patient’s improvement, not the amount of medicine used during treatment, encouraging innovation in treatments and the development of cures.
“The MVP Act is game-changing for high healthcare costs and patient access to treatments. It realigns incentives between insurers and drug manufacturers to ensure that patients get drugs that work. This is especially important for Americans battling cancer or living with a rare disease, whose treatment options are often limited and extremely expensive,” said Sloane Salzburg, Vice President of CAHC. “The legislation will also help to further integrate value-based arrangements into all insurance markets, federal and private.”
The Senate bill is a companion to the House’s MVP Act, sponsored by Representatives Guthrie and Eshoo. The House bill passed out of the Energy & Commerce Committee in 2023.